🇺🇸 FDA
Pipeline program

etrumadenant

ARC-3 (AB928CSP0003)

Phase 1 small_molecule completed

Quick answer

etrumadenant for GastroEsophageal Cancer is a Phase 1 program (small_molecule) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcus Biosciences
Indication
GastroEsophageal Cancer
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials